Nucleus Genomics
Nucleus Genomics is a consumer genomics company providing whole-genome sequencing-based genetic testing for family planning, health screening, and IVF embryo selection. The platform offers direct-to-consumer genetic testing that provides risk and disposition score analyses across an extensive number of diseases and traits, including cancers, diabetes, heart disease, Alzheimer’s disease, height, intelligence, and eye…
Funding snapshot
About
Nucleus Genomics is a consumer genomics company providing whole-genome sequencing-based genetic testing for family planning, health screening, and IVF embryo selection. The platform offers direct-to-consumer genetic testing that provides risk and disposition score analyses across an extensive number of diseases and traits, including cancers, diabetes, heart disease, Alzheimer’s disease, height, intelligence, and eye color. For couples planning a family, Nucleus Preview screens for hereditary diseases and predicts traits of future children. For IVF patients, Nucleus Embryo helps select embryos by screening for chronic health risks including cancers, diabetes, and rare diseases, while also predicting physical traits. The company’s Origin platform represents a family of the most predictive genetic models ever built, trusted by over 165 clinics worldwide. Nucleus partners with fertility clinics including Neway Fertility and Beverly Hills Fertility. Founded in 2021 and headquartered in Manhattan, New York, the company has raised approximately $32 million in Series A funding. Investors include Seven Seven Six, Founders Fund, Shrug Capital, Pareto, Quiet Capital, and Neo. The company has approximately 43 employees.
Business model
Healthcare Booking Platforms > Diagnostics > Internet First Clinical Labs > Genetic Tests > Swab Testing,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Genetic Diagnosis > Suite
Team background
College Wise > University of Pennsylvania
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.